paclitaxel has been researched along with Proteinuria in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, J; Marth, C; Polterauer, S; Reinthaller, A; Schauer, C; Tsibulak, I | 1 |
| Fujii, K; Ishizuka, S; Saeki, S; Sakata, S; Sasaki, J; Sato, R | 1 |
| Fujita, J; Furukawa, H; Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kimura, Y; Makari, Y; Mikami, J; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T | 1 |
| Asakura, M; Houchi, H; Kontani, K; Kosaka, S; Motoki, T; Takahashi, K; Tanaka, H; Yamaguchi, K; Yokomise, H | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Georgoulias, V; Karachaliou, N; Mavroudis, D; Saloustros, E; Vamvakas, L | 1 |
| Kanwar, YS; Kondeti, VK; Ling, G; Liu, F; Liu, Y; Sun, L; Xiang, X; Xiao, L; Yang, Y; Zhan, M; Zhang, D; Zhu, X | 1 |
| Itamochi, H; Sato, S | 1 |
| Coulon Sfairi, MA; Dalenc, F; Delva, R; Espié, M; Hardy-Bessard, AC; Kockler, L; Lortholary, A; Monnier, A; Pavlyuk, M; Pierga, JY; Pivot, X; Serin, D; Veyret, C | 1 |
| Baek, HJ; Chung, ES; Hong, KM; Kim, HA; Lee, EB; Song, YW | 1 |
1 review(s) available for paclitaxel and Proteinuria
| Article | Year |
|---|---|
Bevacizumab and ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Hypertension; Intestinal Perforation; Ovarian Neoplasms; Paclitaxel; Proteinuria; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
1 trial(s) available for paclitaxel and Proteinuria
| Article | Year |
|---|---|
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Hemorrhage; Humans; Hypertension; Middle Aged; Neutropenia; Paclitaxel; Proteinuria; Taxoids; Thromboembolism; Young Adult | 2012 |
8 other study(ies) available for paclitaxel and Proteinuria
| Article | Year |
|---|---|
Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Austria; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Hypertension; Ovarian Neoplasms; Paclitaxel; Proteinuria | 2022 |
Long-term complete response to carboplatin plus paclitaxel combined with bevacizumab in a patient with metastatic spindle cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Carcinoma; Drug Administration Schedule; Humans; Lung Neoplasms; Lymphatic Metastasis; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pleural Neoplasms; Proteinuria; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment | 2017 |
[A Case of Recurrent Gastric Cancer with Grade 3 Proteinuria Caused by Ramucirumab plus Paclitaxel Therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Gastrectomy; Humans; Paclitaxel; Proteinuria; Ramucirumab; Recurrence; Stomach Neoplasms | 2017 |
Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Bevacizumab; Breast Neoplasms; Female; Humans; Hypertension; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Proteinuria; Treatment Outcome | 2018 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles | 2009 |
Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Neoplasm Metastasis; Paclitaxel; Proteinuria; Treatment Outcome | 2010 |
Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192.
Topics: Animals; Cells, Cultured; Creatinine; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Drug Evaluation, Preclinical; Extracellular Matrix; Fibrosis; Gene Expression Regulation; Hypertension, Renal; Kidney; Male; MicroRNAs; Nephrectomy; Paclitaxel; Proteinuria; Rats; Rats, Wistar; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1; Tubulin Modulators | 2011 |
Paclitaxel reduces anti-dsDNA antibody titer and BUN, prolonging survival in murine lupus.
Topics: Animals; Antibodies; Autoimmunity; Blood Urea Nitrogen; DNA; Female; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Paclitaxel; Proteinuria | 1998 |